Biosion, In Global For Global, antibody-drug conjugate, bosakitug TSLP, SynTracer+Flexibody+H3

English

WELCOME TO BIOSION

Biosion is a global biotechnology company that is currently in the clinical stage.

Biosion is a global clinical-stage biotechnology company focused on developing innovative antibody-based therapies to improve outcomes for patients with immune and oncologic diseases. Leveraging its proprietary technologies such as the H³ antibody discovery platform, SynTracer® HT endocytosis platform, and Flexibody® bispecific platform, Biosion creates highly differentiated medicines to address significant unmet medical needs worldwide.

PARTNERING

In Global For Global

NEWS

News and Information

Spot the chance with global eyes, Meet unmet needs where healing lies.

Professional quality

2021-11-12

Biosion, Inc. and Celldex present positive preclinical data at SITC 2021. CDX-585 is the first compound from Celldex’s research and collaboration agreement with Biosion, Inc. and combines Celldex’s IL

2021-11-12

Biosion, Inc. and Celldex present positive preclinical data at SITC 2021. CDX-585 is the first compound from Celldex’s research and collaboration agreement with Biosion, Inc. and combines Celldex’s IL

HAMPTON, N.J., November 12, 2021 — Celldex Therapeutics, Inc. today announced positive preclinical data from CDX-585, the Company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific antibody platform. These data were presented in a poster ses

2020-10-10

Biosion, Inc. Raises ¥200M RMB Financing to Support Further Global Development of Its Innovative Pipeline

2020-10-10

Biosion, Inc. Raises ¥200M RMB Financing to Support Further Global Development of Its Innovative Pipeline

Newark, DE, Nanjing CN – Dec 10, 2020. Biosion Inc. (“Biosion”) today announced completion of ¥200 Million RMB (~$30 Million USD) of financing to transition Biosion into a clinical stage company within twelve months. The financing was led by Lapam Capital, joined by Kaiyuan Capital, Oceanpine Health

2026-06-03

Biosion's Partner Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

2026-06-03

Biosion's Partner Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Biosion's Partner Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052Release time:2025-06-26 11:05:00Nanjing, China, Newark, U.S.A June. 23, 2025-Biosion, a global, clinical-stage biotechnology company, announced that its partner, Aclaris Therapeutics, Inc.

Find us in China, the United States & Australia

Quick Links